PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16819278-0	2006	Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma.	Celecoxib	64-73	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	0-43	
16819278-5	2006	Using proteomics, the 10- to 20-fold increase of heterogeneous nuclear ribonuclear protein C (hnRNP C), which has been suggested to be related with the translation of p(27) mRNA, was observed in celecoxib-treated YD-10(B) cells.	Celecoxib	195-204	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	49-92	
16819278-5	2006	Using proteomics, the 10- to 20-fold increase of heterogeneous nuclear ribonuclear protein C (hnRNP C), which has been suggested to be related with the translation of p(27) mRNA, was observed in celecoxib-treated YD-10(B) cells.	Celecoxib	195-204	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	94-101	
16819278-6	2006	In summary, celecoxib has a potential to induce the protein expression of hnRNP C and its increase subsequently induce the translation of p(27) mRNA, which trigger the inhibition of cell growth via p(27)-regulated cell cycle arrest in YD-10(B) cells.	Celecoxib	12-21	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	74-81	
18468391-6	2008	The results of PBMEC/C1-2 and HUVEC indicated that in comparable therapeutical concentrations celecoxib had a higher potential to impair endothelial cells and to decrease the expression of occludin, ZO-1 and ICAM-1 than indometacin and lornoxicam.	Celecoxib	94-103	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	21-25